Bertil Jönsson

Medical Products Agency — Sweden

Engineering · Physical Sciences

23h-index1.5kcitations93works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Fatigue and fracture mechanics(13), Welding Techniques and Residual Stresses(12), Health Systems, Economic Evaluations, Quality of Life(10), Economic and Financial Impacts of Cancer(9), Traffic and Road Safety(7)

Publications92 total

European Medicines Agency Perspective on Oncology Study Design for Marketing Authorization and Beyond
Clinical Pharmacology & Therapeutics·2017· 6 cited
public health Single-arm trials for cancer drug approval and patient access
Annals of Oncology·2016· 1 citedOpen Access
Welding procedures for fatigue life improvement of the weld toe
Welding in the World·2016· 21 cited
Reply to the letter to the editor ‘Number-Needed-To-Treat for pricing costly anti-cancer drugs. The example of Regorafenib in metastatic colorectal cancer’ by Graziano et al.
Annals of Oncology·2016Open Access
IIW Guidelines on Weld Quality in Relationship to Fatigue Strength
IIW collection·2016· 61 cited
Fitness for Service
IIW collection·2016· 106 cited
Weld Quality Levels for Fatigue Loaded Structures
IIW collection·2016· 1 cited
Inspection, Quality Control, and Documentation
IIW collection·2016
Design for Purpose
IIW collection·2016
IIW Fatigue Assessment Procedures
IIW collection·2016· 1 cited
Root Side Requirements
IIW collection·2016
Introduction
IIW collection·2016· 1 cited
Classification of Weld Imperfections and Features
IIW collection·2016· 1 cited
Early market access of cancer drugs in the EU
Annals of Oncology·2015· 94 cited
Assessment of benefits and risks in development of targeted therapies for cancer — The view of regulatory authorities
Molecular Oncology·2014· 26 citedOpen Access
Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper
Annals of Oncology·2014· 114 citedOpen Access
The changing world of cancer drug development: the regulatory bodies' perspective.
PubMed·2014· 7 cited
Cancer Drug Development and the Evolving Regulatory Framework for Companion Diagnostics in the European Union
Clinical Cancer Research·2014· 44 cited
The risk of whiplash-induced medical impairment in rear-end impacts for males and females in driver seat compared to front passenger seat
IATSS Research·2013· 11 citedOpen Access
The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use
European Journal of Cancer·2013· 54 cited
page 1 of 5Next →

Frequent Co-authors

Francesco Pignatti(9), Zuheir Barsoum(8), Peter Nygren(6), Jörgen Kristensen(5), Rolf Larsson(5), Jonas Bergh(5), Rolf Larsson(5), Ulf Björnstig(5), K Csóka(4), Gary Marquis(3), Spiros Vamvakas(3), Jack Samuelsson(3), Gunnar Liminga(3), H Fridborg(3), Hans Stenlund(3), Mats Y. Svensson(3), R. U. K. Gustafsson(3), Paolo G. Casali(2), Jan Bogaerts(2), Jean‐Yves Blay(2)